• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Coronary Vascular Function and Cardiomyocyte Injury: A Report From the WISE-CVD.冠状动脉血管功能和心肌细胞损伤:来自 WISE-CVD 的报告。
Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):3015-3021. doi: 10.1161/ATVBAHA.120.314260. Epub 2020 Oct 8.
2
Ultra-high sensitivity cardiac troponin-I concentration and left ventricular structure and function in women with ischemia and no obstructive coronary artery disease.缺血且无阻塞性冠状动脉疾病女性的超高敏心肌肌钙蛋白I浓度与左心室结构和功能
Am Heart J Plus. 2022 Jan;13. doi: 10.1016/j.ahjo.2022.100115. Epub 2022 Mar 3.
3
High-Sensitivity Troponin in Patients With Coronary Artery Endothelial Dysfunction.冠状动脉内皮功能障碍患者的高敏肌钙蛋白
J Invasive Cardiol. 2018 Nov;30(11):406-410.
4
Prevalence of Coronary Endothelial and Microvascular Dysfunction in Women with Symptoms of Ischemia and No Obstructive Coronary Artery Disease Is Confirmed by a New Cohort: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD).新队列研究证实:有缺血症状但无阻塞性冠状动脉疾病的女性存在冠状动脉内皮和微血管功能障碍:美国国立卫生研究院赞助的女性缺血综合征评估-冠状动脉血管功能障碍(WISE-CVD)。
J Interv Cardiol. 2019 Mar 11;2019:7169275. doi: 10.1155/2019/7169275. eCollection 2019.
5
Ischemia and No Obstructive Coronary Artery Disease: Prevalence and Correlates of Coronary Vasomotion Disorders.缺血但无阻塞性冠状动脉疾病:冠状动脉血管运动障碍的患病率及其相关因素。
Circ Cardiovasc Interv. 2019 Dec;12(12):e008126. doi: 10.1161/CIRCINTERVENTIONS.119.008126. Epub 2019 Dec 13.
6
Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study.无阻塞性冠状动脉疾病女性冠状动脉反应性检测的安全性:美国国立卫生研究院赞助的 WISE(女性缺血综合征评估)研究结果。
JACC Cardiovasc Interv. 2012 Jun;5(6):646-53. doi: 10.1016/j.jcin.2012.01.023.
7
Coronary endothelial dysfunction appears to be a manifestation of a systemic process: A report from the Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction (WISE-CVD) study.冠状动脉内皮功能障碍似乎是全身过程的一种表现:来自女性缺血综合征评估-冠状动脉血管功能障碍(WISE-CVD)研究的报告。
PLoS One. 2021 Sep 27;16(9):e0257184. doi: 10.1371/journal.pone.0257184. eCollection 2021.
8
Clinical Relevance of Ischemia with Nonobstructive Coronary Arteries According to Coronary Microvascular Dysfunction.根据冠状动脉微血管功能障碍,非阻塞性冠状动脉疾病中的缺血的临床相关性。
J Am Heart Assoc. 2022 May 3;11(9):e025171. doi: 10.1161/JAHA.121.025171. Epub 2022 Apr 27.
9
Oxidative Stress Is Associated With Diastolic Dysfunction in Women With Ischemia With No Obstructive Coronary Artery Disease.氧化应激与无阻塞性冠状动脉疾病缺血女性舒张功能障碍相关。
J Am Heart Assoc. 2020 May 18;9(10):e015602. doi: 10.1161/JAHA.119.015602. Epub 2020 May 7.
10
Rationale and design of the women's ischemia syndrome evaluation mechanisms of coronary microvascular dysfunction leading to preheart failure with preserved ejection fraction (WISE Pre-HFPEF).女性缺血综合征评估机制的原理与设计:冠状动脉微血管功能障碍导致射血分数保留的心力衰竭前期(WISE Pre-HFPEF)
Am Heart J. 2025 Jun;284:47-56. doi: 10.1016/j.ahj.2025.02.017. Epub 2025 Feb 24.

引用本文的文献

1
Accelerated Vascular Aging as a Possible Mechanism of Troponin I Release in the Absence of Clinically Manifested Myocardial Injury.加速血管老化作为无临床表现心肌损伤时肌钙蛋白I释放的一种可能机制。
J Am Heart Assoc. 2025 Apr;14(7):e037718. doi: 10.1161/JAHA.124.037718. Epub 2025 Mar 27.
2
Evaluation of coronary microvascular dysfunction using magnetocardiography: A new application to an old technology.利用心磁图评估冠状动脉微血管功能障碍:一项旧技术的新应用。
Am Heart J Plus. 2024 Jul 10;44:100424. doi: 10.1016/j.ahjo.2024.100424. eCollection 2024 Aug.
3
Latest from the WISE: Contributions to the Understanding of Ischemia and Heart Failure among Women with No Obstructive Coronary Arteries.WISE最新消息:对无阻塞性冠状动脉女性缺血与心力衰竭认识的贡献
Rev Cardiovasc Med. 2023 Mar 15;24(3):90. doi: 10.31083/j.rcm2403090. eCollection 2023 Mar.
4
RNAseq of INOCA patients identifies innate, invariant, and acquired immune changes: potential autoimmune microvascular dysfunction.INOCA患者的RNA测序确定了先天性、不变性和获得性免疫变化:潜在的自身免疫性微血管功能障碍。
Front Cardiovasc Med. 2024 Jun 24;11:1385457. doi: 10.3389/fcvm.2024.1385457. eCollection 2024.
5
Expanding landscape of coronary microvascular disease in co-morbid conditions: Metabolic disease and beyond.合并症中心血管疾病的微血管病变:代谢疾病及其他。
J Mol Cell Cardiol. 2024 Jul;192:26-35. doi: 10.1016/j.yjmcc.2024.05.004. Epub 2024 May 10.
6
Klotho/FGF23 Axis Regulates Cardiomyocyte Apoptosis and Cytokine Release through ERK/MAPK Pathway.Klotho/FGF23 轴通过 ERK/MAPK 通路调节心肌细胞凋亡和细胞因子释放。
Cardiovasc Toxicol. 2023 Oct;23(9-10):317-328. doi: 10.1007/s12012-023-09805-6. Epub 2023 Sep 13.
7
Imaging of heart disease in women: review and case presentation.女性心脏病影像学检查:综述与病例报告
Eur J Nucl Med Mol Imaging. 2022 Dec;50(1):130-159. doi: 10.1007/s00259-022-05914-6. Epub 2022 Aug 17.
8
Ultra-high sensitivity cardiac troponin-I concentration and left ventricular structure and function in women with ischemia and no obstructive coronary artery disease.缺血且无阻塞性冠状动脉疾病女性的超高敏心肌肌钙蛋白I浓度与左心室结构和功能
Am Heart J Plus. 2022 Jan;13. doi: 10.1016/j.ahjo.2022.100115. Epub 2022 Mar 3.
9
Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials.我们是否变得更明智了?将女性纳入冠状动脉疾病试验的智能试验的进展和当代需求。
Contemp Clin Trials. 2022 Jun;117:106762. doi: 10.1016/j.cct.2022.106762. Epub 2022 Apr 20.
10
The relation of circulating cell division cycle 42 expression with Th1, Th2, and Th17 cells, adhesion molecules, and biochemical indexes in coronary heart disease patients.循环细胞周期蛋白 42 表达与冠心病患者 Th1、Th2、Th17 细胞、黏附分子和生化指标的关系。
Ir J Med Sci. 2022 Oct;191(5):2085-2090. doi: 10.1007/s11845-021-02836-4. Epub 2021 Nov 22.

本文引用的文献

1
Design, methodology and baseline characteristics of the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD).《女性缺血综合征评估-冠状动脉功能障碍(WISE-CVD)》的设计、方法学和基线特征。
Am Heart J. 2020 Feb;220:224-236. doi: 10.1016/j.ahj.2019.11.017. Epub 2019 Dec 5.
2
Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes in Women.异常冠状动脉反应对女性长期临床结局的影响。
J Am Coll Cardiol. 2019 Feb 19;73(6):684-693. doi: 10.1016/j.jacc.2018.11.040.
3
Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain.hsTnI 单分子检测与稳定型胸痛患者的短期风险。
J Am Coll Cardiol. 2019 Jan 29;73(3):251-260. doi: 10.1016/j.jacc.2018.10.065.
4
Global Adoption of High-Sensitivity Cardiac Troponins and the Universal Definition of Myocardial Infarction.全球范围内对高敏心肌肌钙蛋白的采用和心肌梗死的通用定义。
Clin Chem. 2019 Mar;65(3):484-489. doi: 10.1373/clinchem.2018.298059. Epub 2019 Jan 9.
5
"Ultra-sensitive" cardiac troponins: Requirements for effective implementation in clinical practice.超敏肌钙蛋白:在临床实践中有效实施的要求。
Biochem Med (Zagreb). 2018 Oct 15;28(3):030501. doi: 10.11613/BM.2018.030501.
6
Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries.心肌梗死和非阻塞性冠状动脉疾病患者与高敏心肌肌钙蛋白 T 水平相关的预后。
Am Heart J. 2018 Jun;200:60-66. doi: 10.1016/j.ahj.2018.03.005. Epub 2018 Mar 10.
7
High-Sensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Long-Term Outcomes.高敏肌钙蛋白 I 水平与冠状动脉疾病严重程度、进展和长期结局。
J Am Heart Assoc. 2018 Feb 21;7(5):e007914. doi: 10.1161/JAHA.117.007914.
8
The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform.心肌肌钙蛋白 I 生物标志物分析的不断发展:从蛋白质到蛋白异构体。
Expert Rev Proteomics. 2017 Nov;14(11):973-986. doi: 10.1080/14789450.2017.1387054. Epub 2017 Oct 16.
9
Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade.缺血与无阻塞性冠状动脉疾病(INOCA):为未来十年制定循证疗法与研究议程
Circulation. 2017 Mar 14;135(11):1075-1092. doi: 10.1161/CIRCULATIONAHA.116.024534.
10
Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease.胸痛且冠状动脉无阻塞的患者中心血管功能障碍的患病率。
JACC Cardiovasc Interv. 2015 Sep;8(11):1445-1453. doi: 10.1016/j.jcin.2015.06.017.

冠状动脉血管功能和心肌细胞损伤:来自 WISE-CVD 的报告。

Coronary Vascular Function and Cardiomyocyte Injury: A Report From the WISE-CVD.

机构信息

Emory Clinical Cardiovascular Research Institute, Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.A., P.K.M., Y.X., Y.-A.K.).

Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (J.W., O.Q., B.A., B.S., T.D.H., J.V.E., C.N.B.M.).

出版信息

Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):3015-3021. doi: 10.1161/ATVBAHA.120.314260. Epub 2020 Oct 8.

DOI:10.1161/ATVBAHA.120.314260
PMID:33028098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8079158/
Abstract

OBJECTIVE

Women with symptoms or signs of myocardial ischemia but no obstructive coronary artery disease (INOCA) often have coronary vascular dysfunction and elevated risk for adverse cardiovascular events. We hypothesized that u-hscTnI (ultra-high-sensitivity cardiac troponin I), a sensitive indicator of ischemic cardiomyocyte injury, is associated with coronary vascular dysfunction in women with INOCA. Approach and Results: Women (N=263) with INOCA enrolled in the WISE-CVD study (Women's Ischemic Syndrome Evaluation-Coronary Vascular Dysfunction) underwent invasive coronary vascular function testing and u-hscTnI measurements (Simoa HD-1 Analyzer; Quanterix Corporation, Lexington, MA). Logistic regression models, adjusted for traditional cardiovascular risk factors were used to evaluate associations between u-hscTnI and coronary vascular function. Women with coronary vascular dysfunction (microvascular constriction and limited coronary epicardial dilation) had higher plasma u-hscTnI levels (both =0.001). u-hscTnI levels were associated with microvascular constriction (odds ratio, 1.38 per doubling of u-hscTnI [95% CI, 1.03-1.84]; =0.033) and limited coronary epicardial dilation (odds ratio, 1.37 per doubling of u-hscTnI [95% CI, 1.04-1.81]; =0.026). u-hscTnI levels were not associated with microvascular dilation or coronary epicardial constriction.

CONCLUSIONS

Our findings indicate that higher u-hscTnI is associated with coronary vascular dysfunction in women with INOCA. This suggests that ischemic cardiomyocyte injury in the setting of coronary vascular dysfunction has the potential to contribute to adverse cardiovascular outcomes observed in these women. Additional studies are needed to confirm and investigate mechanisms underlying these findings in INOCA. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00832702.

摘要

目的

有心肌缺血症状或体征但无阻塞性冠状动脉疾病(INOCA)的女性常伴有冠状动脉血管功能障碍和不良心血管事件风险升高。我们假设超敏心肌肌钙蛋白 I(u-hscTnI),一种缺血性心肌细胞损伤的敏感指标,与 INOCA 女性的冠状动脉血管功能障碍有关。

方法和结果

WISE-CVD 研究(女性缺血综合征评估-冠状动脉血管功能障碍)纳入了 263 名 INOCA 女性患者,进行了有创冠状动脉血管功能检测和 u-hscTnI 测量(Simoa HD-1 分析仪;Quanterix 公司,列克星敦,马萨诸塞州)。使用调整了传统心血管危险因素的逻辑回归模型来评估 u-hscTnI 与冠状动脉血管功能之间的关系。有冠状动脉血管功能障碍(微血管收缩和有限的冠状动脉心外膜扩张)的女性,其血浆 u-hscTnI 水平更高(均<0.001)。u-hscTnI 水平与微血管收缩(比值比,u-hscTnI 每加倍 1.38[95%CI,1.03-1.84];=0.033)和有限的冠状动脉心外膜扩张(比值比,u-hscTnI 每加倍 1.37[95%CI,1.04-1.81];=0.026)相关。u-hscTnI 水平与微血管扩张或冠状动脉心外膜收缩无关。

结论

我们的研究结果表明,INOCA 女性中较高的 u-hscTnI 与冠状动脉血管功能障碍有关。这表明在冠状动脉血管功能障碍的情况下,缺血性心肌细胞损伤有可能导致这些女性发生不良心血管结局。需要进一步的研究来证实和探讨 INOCA 中这些发现的机制。

登记

网址:https://www.clinicaltrials.gov;唯一标识符:NCT00832702。